PDB8 WILL IRBESARTAN LEAD TO COST SAVINGS DUE TO DELAYED END STAGE RENAL DISEASE IN HYPERTENSIVE TYPE-2 DIABETICS IN GERMANY?  by Pirk, O et al.
737Abstracts
OBJECTIVES: A recent randomized trial demonstrated that
twice daily biphasic insulin aspart 30/70 (BIAsp30/70) led to sig-
niﬁcantly (p = 0.0057) better glycaemic control compared to
bedtime insulin glargine in insulin-naïve type-2 diabetes patients
on oral antidiabetics (HbA1c reduced by -2.79% vs. -2.36%
from baseline). Patients gained more weight with BIAsp30/70
than with glargine (5.4 vs. 3.5kg, p = 0.0013), but weight gain
per unit insulin was similar. The CORE Diabetes Model, a peer-
reviewed, validated, model was used to project the long term cost
effectiveness of BIAsp30/70 versus glargine. METHODS: The
CORE Diabetes model employs standard Markov/Monte Carlo
simulation techniques to describe the long-term incidence and
progression of diabetes-related complications. Transition proba-
bilities were derived from major diabetes studies. Clinical effects
of comparators were derived from the INITIATE study. The
analysis was performed using published country-speciﬁc costs,
health care resource utilization and clinical data, and recom-
mended discount rates. A lifetime horizon and payers’ perspec-
tive was taken. Only direct costs were considered. Sensitivity
analyses were performed. RESULTS: Discounted quality-
adjusted life years (QALY) were improved by 0.13–0.25 years
with BIAsp30/70 versus glargine depending on country-speciﬁc
discount rates. Lifetime cost savings were observed 
with BIAsp30/70 in the Danish, Dutch, Finnish, French, Nor-
wegian, Spanish, and Swedish settings. Overall costs were
increased with BIAsp30/70 versus glargine in the German and
UK settings, with incremental cost-effectiveness ratios of 3692€
and £1541/QALY gained respectively. Results were most sensi-
tive to changes in baseline HbA1c and to the relative costs of
BIAsp30/70 versus glargine. CONCLUSIONS: Improvements in
glycemic control outweighed the greater increase in body weight,
leading to improved quality-adjusted life expectancy with
BIAsp30/70 versus glargine. BIAsp30/70 was projected to lead
to overall cost savings or would be considered cost-effective
versus glargine, with costs/QALY falling well below commonly
accepted international thresholds.
PDB8
WILL IRBESARTAN LEAD TO COST SAVINGS DUE TO
DELAYED END STAGE RENAL DISEASE IN HYPERTENSIVE
TYPE-2 DIABETICS IN GERMANY?
Pirk O1, Ratzmann KP2, Carels J3, Bramlage P4, Kirch W4
1Fricke & Pirk GmbH, Nuremberg, Germany; 2Diabetische
Schwerpunktpraxis, Berlin, Germany; 3Sanoﬁ-Synthelabo, Berlin,
Germany; 4Medizinische Fakultaet Carl Gustav Carus der Technischen
Universitaet Dresden, Dresden, Germany
OBJECTIVES: Type-2 diabetes is a major health problem. 30%
of all patients being on dialysis suffer from a diabetic Endstage
Renal Disease (ESRD). The Angiotensin-2-Receptor-Blocker
(ARB) Irbesartan has proven its capability to prevent or delay
an ESRD. Based on the results of the multicentre double-blind,
randomized, placebo-controlled Irbesartan Diabetic Nephropa-
thy Trial (IDNT) the presented study aims to show that a treat-
ment of renal diseases in hypertensive type-2 diabetics with the
ARB Irbesartan is cost saving for the German health care system.
METHODS: A cost-effectiveness analysis from the German
payers’ perspective was conducted taking direct costs into
account. 1715 type-2 diabetics with hypertension and limited
renal function were included in IDNT (2.6 years, subgroup with
300mg/d Irbesartan). The patient number needed to treat (NNT)
to prevent one ESRD was the efﬁcacy parameter for this analy-
sis. Public sources were used for cost data and information on
dialysis and transplantation in diabetics with ESRD. Actual drug
prices were used taking into account discounts and co-payments
effective in Germany due to new legislation since January 2004.
Due to conservative calculation no discounting was performed,
follow-up treatment costs were not included. RESULTS: The
NNT for the primary endpoint ESRD calculated to 28 during
the study period of 2.6 years in IDNT. That means additional
treatment costs of €25,007.—lead to one prevented ESRD (incre-
mental cost-effectiveness-ratio). The prevented ESRD (82% dial-
ysis, 18% transplantation) is worth €45,766.—which shows a
beneﬁt for Irbesartan treatment of €20,758.—after 2.6 years or
€7984.—per year assuming a linear trend towards delay in
ESRD. A sensitivity analysis stated the robustness of the data.
CONCLUSIONS: Based on epidemiologic data our results
suggest savings for the German health care system of €3.2 billion
after 2.6 years if annually additional €681 million were invested
in the treatment of type-2 diabetics with Irbesartan.
PDB9
THE VALUE OF ORAL MONOTHERAPY ALTERNATIVES IN THE
FIRST-LINE TREATMENT OF TYPE-2 DIABETES MELLITUS
Tilden D1, Stynes G1, Swift M2, Cockle S1, Haycox A3, Aristides M1
1M-TAG Limited, Hammersmith, UK; 2Takeda UK Limited, High
Wycombe, UK; 3University of Liverpool, Liverpool, UK
OBJECTIVES: To construct a lifetime model evaluating poten-
tial health beneﬁts and costs applying to Scottish Type-2 diabetes
mellitus patients initiating ﬁrst-line oral monotherapy, for whom
metformin is inappropriate because of contra-indications or
intolerance. When lifestyle modiﬁcation (diet and exercise)
affords inadequate glycaemic control, these patients currently
have no alternative to sulphonylurea (SU) therapy. The model
compared novel agent pioglitazone (PIO) versus generic SU treat-
ment. METHODS: A decision-analytic Markov model was 
constructed using published (UKPDS) cost data for diabetes
management and co-morbidity treatment. Three prospective
treatment pathways were explored: ﬁrst-line PIO/second-line
PIO + SU combination/third-line insulin; ﬁrst-line SU/second-
line PIO + SU combination/third-line insulin; and ﬁrst-line
SU/second-line insulin. The model incorporated efﬁcacy evidence
of glycaemic control under PIO and SU, measured as initial
HbA1c improvements and the rate of disease progression in
terms of HbA1c (the coefﬁcient of failure). RESULTS: Patients
treated with PIO achieved better HbA1c control and improved
serum lipid proﬁles, which translated into fewer diabetic com-
plications, better quality of life and improved overall survival.
Additional drug costs of PIO over SU were partly offset by lower
costs to treat and manage diabetes complications, and delayed
insulin therapy. The estimated incremental cost per QALY gained
of PIO was £2415 compared to SU (when followed by second-
line PIO/SU and third-line insulin therapy). The incremental cost
per QALY gained of PIO was £1514 compared to SU (when fol-
lowed by second-line insulin therapy). CONCLUSIONS: Clini-
cal trial evidence indicated superior glycaemic (HbA1c) control
in patients treated with PIO, in comparison with those treated
with SU. The model showed that PIO is a cost-effective inter-
vention and thus a valuable addition to ﬁrst-line treatment
options for patients intolerant and/or contra-indicated to met-
formin. Importantly, initiating PIO as second-line combination
treatment after ﬁrst-line SU in this patient group was less efﬁ-
cient than providing PIO monotherapy in a ﬁrst-line setting.
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OBJECTIVES: To develop a lifetime model of Type-2 diabetes
mellitus and its sequelae, to compare the costs and beneﬁts of
